Endurant Capital Management LP Puma Biotechnology, Inc. Transaction History

Endurant Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $503,375 - $1.17 Million	-25,081 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $647,128 - $940,063	-15,707 Reduced 38.51%	25,081 $1.15 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $777,050 - $1.1 Million	16,088 Added 65.13%	40,788 $2.41 Million
Q1 2018 May 15, 2018	SELL	$59.7 - $99.25 $310,440 - $516,100	-5,200 Reduced 17.39%	24,700 $1.68 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $797,725 - $1.13 Million	8,500 Added 39.72%	29,900 $2.96 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $1.54 Million - $2.56 Million	21,400	21,400 $2.56 Million

100

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $125M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.